论文部分内容阅读
本文报道肝细胞生长素(HCF)治疗重症肝炎40例疗效,并探讨与疗效有关的因素。其方法为在综合基础治疗的基础上同用HGC 80～120mg加入输液中静滴,每日1次,疗程10～30天,部分延长到30天以上,并与同期未用HGF,病情相近的重症肝炎34例作对照.结果治疗组与对照组病死率为27.5％及32.3％,又从疗效方面观察到亚重症疗效优于慢重肝;肝功衰早期优于中晚期,40岁以下患者优于40岁以上者;血清总胆红素量≥342μmol/L及有并发症者疗效差;且观察到剂量方面以每日80～120mg较合适,但疗程则以≥30天组为优。
This article reports the efficacy of hepatocyte growth-promoting factor (HCF) in the treatment of 40 cases of severe hepatitis, and to explore the factors associated with efficacy. The method is based on the basis of comprehensive treatment with HGC 80 ~ 120mg intravenous infusion infusion once a day for 10 to 30 days, partially extended to more than 30 days, and with the same period without HGF, similar to the disease 34 cases of severe hepatitis as control.Results The mortality of treatment group and control group was 27.5% and 32.3%, respectively, and from the efficacy point of view, the treatment of sub-heavy disease was better than that of chronic severe liver disease. The early stage of liver failure was better than the middle and advanced stage, Better than 40 years of age; serum total bilirubin ≥ 342μmol / L and complications were poor efficacy; and the dose was observed daily 80 ~ 120mg more appropriate, but the course of treatment is ≥ 30 days group is excellent.